Io Biotech APS

17 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Apr 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 16, 2026
The maintenance fee for Indoleamine 2,3-dioxygenase based immunotherapy (US 11,648,302) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
1 fee due Jul 23, 2027
The maintenance fee for Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof (US 11,878,053) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 11,648,302	Indoleamine 2,3-dioxygenase based immunotherapy In force Ends no later than Apr 17, 2029 · From the USPTO record	In force	Ends no later than Apr 17, 2029	From the USPTO record
US 12,233,103	Indoleamine 2,3-dioxygenase based immunotherapy In force Term ends Apr 17, 2029 · From the USPTO record	In force	Term ends Apr 17, 2029	From the USPTO record
US 11,324,813	Indoleamine 2,3-dioxygenase based immunotherapy In force Term ends May 28, 2029 · From the USPTO record	In force	Term ends May 28, 2029	From the USPTO record
US 10,258,678	Indoleamine 2,3-dioxygenase based immunotherapy In force Term ends Oct 7, 2029 · From the USPTO record	In force	Term ends Oct 7, 2029	From the USPTO record
US 9,433,666	Indoleamine 2,3-dioxygenase based immunotherapy In force Term ends Sep 16, 2030 · From the USPTO record	In force	Term ends Sep 16, 2030	From the USPTO record
US 9,669,078	PD-L1 based immunotherapy In force Term ends May 11, 2033 · From the USPTO record	In force	Term ends May 11, 2033	From the USPTO record
US 10,736,950	Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof In force Term ends Mar 1, 2036 · From the USPTO record	In force	Term ends Mar 1, 2036	From the USPTO record
US 11,298,413	Vaccine Compositions Comprising C-C Motif Chemokine 22 (CCL22) or Fragments Thereof In force Term ends Sep 16, 2036 · High confidence	In force	Term ends Sep 16, 2036	High confidence
US 12,496,333	Vaccine Compositions Comprising C-C Motif Chemokine 22 (CCL22) or Fragments Thereof In force Term ends Sep 16, 2036 · High confidence	In force	Term ends Sep 16, 2036	High confidence
US 12,551,543	Vaccine Compositions Comprising C-C Motif Chemokine 22 (CCL22) or Fragments Thereof In force Term ends Sep 16, 2036 · High confidence	In force	Term ends Sep 16, 2036	High confidence

10 of 17 patents shown.

Pro members see all 17.

Pro members: see all 17 patents

Also on record, not counted in the 17: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 1 abandoned · 8 no status recorded

List them